Previous Article | Next Article ![]()
Infection and Immunity, May 2000, p. 2827-2836, Vol. 68, No. 5
MRC Center for Molecular and Cellular
Biology1 and Departments of Medical
Biochemistry,2 Anatomical
Pathology,4 and Internal
Medicine,5 University of Stellenbosch Medical
School, Cape Town, South Africa, and Glaxo Wellcome Research
and Development, Medicines Research Center, Stevenage, United
Kingdom3
Received 14 June 1999/Returned for modification 25 August
1999/Accepted 10 October 1999
Human tuberculous granulomas from five adults undergoing surgery
for hemoptysis were analyzed by nonradioactive in situ hybridization for tumor necrosis factor alpha (TNF-
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
In Situ Production of Gamma Interferon,
Interleukin-4, and Tumor Necrosis Factor Alpha mRNA in Human Lung
Tuberculous Granulomas
), gamma interferon (IFN-
), and interleukin-4 (IL-4) gene expression. All of the patients produced
TNF-
mRNA. Three patients stained positive for both IFN-
and IL-4
mRNA; the other two stained positive for IFN-
but not IL-4 mRNA.
Heterogeneity between the granulomas was observed in those patients
staining positive for both IFN-
and IL-4 mRNA; these patients
exhibited granulomas having IFN-
and not IL-4 mRNA as well as
granulomas positive for both cytokine mRNAs. There was no evidence of
caseation in these granulomas, and the cytokine patterns may represent
events in the evolution of the granuloma. However, in those granulomas
exhibiting caseous necrosis, very little IFN-
or IL-4 mRNA was
observed, implying that progression of the granuloma is accompanied by
a down regulation of T-cell responses. TNF-
mRNA expression was
highest in patients with both IFN-
and IL-4 mRNA. Populations of
CD68 positive macrophage-like cells within the granulomas produce mRNA
for TNF-
, IFN-
, and IL-4. This implies that macrophages within
the tuberculous granuloma may not be dependent on T-cell cytokines for
modulation of their function but may be able to regulate their own
activation state and that of the surrounding T cells. These findings
have implications on the delivery of immunotherapies to patients with tuberculosis.
*
Corresponding author. Mailing address: Glaxo Wellcome
Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom. Phone: 99 1438 76 4968. Fax: 99 1438 76 4898. E-mail:
PTL46978{at}GLAXOWELLCOME.CO.UK.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|